The predictive markers in PD-1/PD-L1 antibody therapy are mainly the number of cytotoxic T-lymphocytes inside tumor tissues and the expression level of PD-L1 in cancer cells (Chen et al., 2016). The gene discussed is PDCD1; the disease is neoplasm.